Having trouble viewing this email? View in your browser.
ESCMID Logo

4 October 2016
WEEKLY NEWS

Dear colleagues,

Young scientists may now cast their votes in the election of four new members – two each for clinical microbiology and infectious diseases – for the Trainee Association of ESCMID’s Steering Committee.

Best regards, your ESCMID communications editors

 

Registration for ECCMID 2017 in Vienna is now open

The congress registration includes the use of public transportation within the city of Vienna and for the first time we also offer cancellation insurance.
The programme committee has prepared an attractive scientific programme. Have a look for example at our keynote lectures, which include presentations by renowned experts on antibiotic stewardship, diagnostic bacteriology, elimination of malaria and HIV or the role of intestinal microbiota to combat antimicrobial-resistant bacteria.

› Read more
 

CMI highlight: tigecycline in patients with severe Clostridium difficile infection

Researchers in Hungary studied the efficacy of tigecycline compared to standard therapy with oral vancomycin plus intravenous metronidazole in adults treated for severe Clostridium difficile infection (sCDI). Patients treated with tigecycline had significantly better outcomes of clinical cure, less complicated disease courses and less CDI sepsis compared to patients receiving standard therapy. Tigecycline usage was not associated with adverse drug reactions or need for colectomy. Rates of ileus, toxic megacolon, mortality and relapse were similar between the two groups, the study showed. The researchers concluded that the favourable outcomes suggest that tigecycline should be considered as a potential candidate for therapeutic usage in cases of sCDI refractory to standard treatment.

› Read more
 

ESCMID/ASM AMR conference outlines solutions to speed up drug development

The ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance has come to a close in Vienna, Austria. The conference addressed issues such as the reliance on very robust preclinical studies, innovative clinical trial design, strong academic-industrial partnerships, and a requirement for early engagement with regulatory bodies in order to facilitate the processes for accelerated antimicrobial development. The presentations can be found in the ESCMID eLibrary.

› Read more
 

Call for ESCMID Excellence and Young Investigator Awards open now

Nominations are accepted until 15 November 2016 at 12:00 noon CET for the Award for Excellence in recognition of an outstanding lifetime contribution to science, education or professional affairs in the field of infection as well as for the Young Investigator Award, which rewards outstanding research and stimulates further studies at the highest scientific level.

› Read more
ESCMID Executive Office
P.O. Box 214
4010 Basel
Switzerland
Phone +41 61 5080 173
info@escmid.org
www.escmid.org
Follow ESCMID
Visit us on LinkedIn Visit us on YouTube
 
The ESCMID Newsletter is issued on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) by the ESCMID Executive Office. It contains announcements of ESCMID-related matters and other information of interest to professionals in the infection field.

Tip: To ensure that you receive the ESCMID newsletter in your inbox, add newsletter@escmid.org to your email program’s address book.

You have received this email as a contact of ESCMID or one of its affiliated societies. You can unsubscribe or change your newsletter subscriptions here.